Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Phase II Trial to Investigate the Safety and Efficacy of Sym004 in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Anti-EGFR Monoclonal Antibody-based Therapy

NCT01417936 is registered in ClinicalTrials.gov with Symphogen A/S as lead sponsor.

NCT NCT01417936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01417936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Phase II Trial to Investigate the Safety and Efficacy of Sym004 in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Anti-EGFR Monoclonal Antibody-based Therapy
Lead sponsor
Symphogen A/S
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
October 31, 2012
Enrollment
26 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck